Contract Research & Services
Clinical Trials

Clinical Trials News

View news from other Pharmaceutical sectors:
121-135 of 4358 results
Alzheimer’s drug Solanezumab fails to slow cognitive decline in clinical study
By PBR Staff Writer
A study has demonstrated that Alzheimer’s drug, solanezumab, targeting amyloid plaques, did not significantly slow cognitive decline.
Contract Research & Services > Clinical Trials > News
Pfizer’s rituximab biosimilar succeeds in phase III follicular lymphoma trial
By PBR Staff Writer
Pfizer’s PF-05280586, a potential biosimilar to rituximab, has met its primary endpoint of overall response rate in a clinical trial of patients with CD20-positive follicular lymphoma and low tumor burden.
Contract Research & Services > Clinical Trials > News
SymBio begins phase 1 trial for treakisym in progressive solid tumors
SymBio Pharmaceuticals has launched a phase 1 study in Japan for oral Treakisym in patients with progressive solid tumors.
Contract Research & Services > Clinical Trials > News
ImmuPharma completes phase 3 trial of Lupus drug
ImmuPharma has completed its 52-week, randomised, double-blinded, phase 3 clinical trial of Lupuzor, its lead candidate for the potential breakthrough compound for Lupus.
Contract Research & Services > Clinical Trials > News
Merck’s Keytruda regimen succeeds in phase 3 NSCLC trial
By PBR Staff Writer
Merck’s Keytruda (pembrolizumab) in combination with pemetrexed (Alimta) plus platinum chemotherapy has significantly improved overall survival (OS) and progression-free survival (PFS) of certain type of lung cancer patients in a phase 3 trial.
Contract Research & Services > Clinical Trials > News
Allergy Therapeutics completes patient recruitment in PQ Birch phase III clinical trial
Allergy Therapeutics has completed recruitment of patients in the PQ Birch phase III clinical trial.
Contract Research & Services > Clinical Trials > News
BerGenBio meets first efficacy endpoint in phase II trial with selective AXL inhibitor BGB324 in NSCLC
BerGenBio announced that it met the first efficacy endpoint in the phase II clinical trial evaluating BGB324 (bemcentinib), a selective AXL inhibitor, in combination with erlotinib in patients with advanced non-small cell lung cancer (NSCLC) who have progressed on an approved EGFR inhibitor.
Contract Research & Services > Clinical Trials > News
Inovio, Parker Institute to jointly evaluate cancer immunotherapy combinations
Inovio Pharmaceuticals and the Parker Institute for Cancer Immunotherapy have signed a clinical collaboration agreement to assess novel combination regimens within the field of immuno-oncology.
Contract Research & Services > Clinical Trials > News
Axovant scraps dementia drug development after negative results
By PBR Staff Writer
Axovant Sciences said it will no longer develop intepirdine, its lead candidate for dementia, after failing to meet several goals in recent studies.
Contract Research & Services > Clinical Trials > News
Momenta, Mylan to start trial of biosimilar to eye drug Eylea
By PBR Staff Writer
Momenta Pharmaceuticals and Mylan have unveiled plans to commence pivotal clinical study of a biosimilar to Regeneron’s eye drug Eylea (aflibercept).
Contract Research & Services > Clinical Trials > News
Centrexion secures funding to begin trial of knee osteoarthritis pain drug
By PBR Staff Writer
Centrexion Therapeutics has secured $67m funding to launch phase 3 progam of CNTX-4975 therapy for the treatment of chronic pain due to knee osteoarthritis (OA).
Contract Research & Services > Clinical Trials > News
Atara gets FDA approval to start two phase 3 studies to assess tabelecleucel in patients with EBV+PTLD
Atara Biotherapeutics has received clearance from the US Food and Drug Administration (FDA) to initiate two phase 3 clinical studies with tabelecleucel (formerly known as ATA129) in patients with rituximab-refractory Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+PTLD).
Contract Research & Services > Clinical Trials > News
Study shows experimental diabetes drug could enhance Alzheimer’s signs in mice
By PBR Staff Writer
A study conducted by the UK and Chinese researchers showed that an experimental diabetes drug may have improved the memory and brain function in mice with symptoms of Alzheimer’s disease.
Contract Research & Services > Clinical Trials > News
AbbVie's upadacitinib succeeds in phase 3 rheumatoid arthritis study
AbbVie says that its investigational oral JAK1-selective inhibitor upadacitinib (ABT-494) has demonstrated positive results as monotherapy in phase 3 rheumatoid arthritis study, meeting all primary and key secondary endpoints.
Contract Research & Services > Clinical Trials > News
Bristol-Myers makes equity investment in Taris Biomedical
By PBR Staff Writer
Bristol-Myers Squibb has made an equity investment in Taris Biomedical, a therapeutically urology company engaged in the development of treatments for patients suffering from difficult-to-treat bladder diseases.
Contract Research & Services > Clinical Trials > News
121-135 of 4358 results